#BEGIN_DRUGCARD DB02338

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C21H30N7O17P3

# Chemical_IUPAC_Name:
{[(2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-[({[({[(2S,3R,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-4-hydroxyoxolan-3-yl]oxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nadph Dihydro-Nicotinamide-Adenine-Dinucleotidephosphate

# HET_ID:
NDP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1,3-4,7-8,10-11,13-16,20-21,29-31H,2,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15+,16+,20+,21+/m0/s1

# InChI_Key:
InChIKey=ACFIXJIJDZMPPO-XCSFTKGKSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2338

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
745.4209

# Molecular_Weight_Mono:
745.091102105

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1H6V

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.1

# Predicted_LogS:
-2.1

# Predicted_Water_Solubility:
5.45e+00 g/l

# Primary_Accession_No:
DB02338

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5702548

# PubChem_Substance_ID:
46508520

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02321

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=CN(C=CC1)[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H]2O[C@H]([C@H](OP(O)(O)=O)[C@H]2O)N2C=NC3=C2N=CN=C3N)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:01 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TXNRD1

# Drug_Target_1_GenBank_ID_Gene:
X91247

# Drug_Target_1_GenBank_ID_Protein:
1237038

# Drug_Target_1_GeneCard_ID:
TXNRD1

# Drug_Target_1_Gene_Name:
TXNRD1

# Drug_Target_1_Gene_Sequence:
>1494 bp
ATGAACGGCCCTGAAGATCTTCCCAAGTCCTATGACTATGACCTTATCATCATTGGAGGT
GGCTCAGGAGGTCTGGCAGCTGCTAAGGAGGCAGCCCAATATGGCAAGAAGGTGATGGTC
CTGGACTTTGTCACTCCCACCCCTCTTGGAACTAGATGGGGTCTTGGAGGAACATGTGTG
AATGTGGGTTGCATACCTAAAAAACTGATGCATCAAGCAGCTTTGTTAGGACAAGCCCTG
CAAGACTCTCGAAATTATGGATGGAAAGTCGAGGAGACAGTTAAGCATGATTGGGACAGA
ATGATAGAAGCTGTACAGAATCACATTGGCTCTTTGAATTGGGGCTACCGAGTAGCTCTG
CGGGAGAAAAAAGTCGTCTATGAGAATGCTTATGGGCAATTTATTGGTCCTCACAGGATT
AAGGCAACAAATAATAAAGGCAAAGAAAAAATTTATTCAGCAGAGAGTTTTCTCATTGCC
ACTGGTGAAAGACCACGTTACTTGGGCATCCCTGGTGACAAAGAATACTGCATCAGCAGT
GATGATCTTTTCTCCTTGCCTTACTGCCCGGGTAAGACCCTGGTTGTTGGAGCATCCTAT
GTCGCTTTGGAGTGCGCTGGATTTCTTGCTGGTATTGGTTTAGGCGTCACTGTTATGGTT
AGGTCCATTCTTCTTAGAGGATTTGACCAGGACATGGCCAACAAAATTGGTGAACACATG
GAAGAACATGGCATCAAGTTTATAAGACAGTTCGTACCAATTAAAGTTGAACAAATTGAA
GCAGGGACACCAGGCCGACTCAGAGTAGTAGCTCAGTCCACCAATAGTGAGGAAATCATT
GAAGGAGAATATAATACGGTGATGCTGGCAATAGGAAGAGATGCTTGCACAAGAAAAATT
GGCTTAGAAACCGTAGGGGTGAAGATAAATGAAAAGACTGGAAAAATACCTGTCACAGAT
GAAGAACAGACCAATGTGCCTTACATCTATGCCATTGGCGATATATTGGAGGATAAGGTG
GAGCTCACCCCAGTTGCAATCCAGGCAGGAAGATTGCTGGCTCAGAGGCTCTATGCAGGT
TCCACTGTCAAGTGTGACTATGAAAATGTTCCAACCACTGTATTTACTCCTTTGGAATAT
GGTGCTTGTGGCCTTTCTGAGGAGAAAGCTGTGGAGAAGTTTGGGGAAGAAAATATTGAG
GTTTACCATAGTTACTTTTGGCCATTGGAATGGACGATTCCGTCAAGAGATAACAACAAA
TGTTATGCAAAAATAATCTGTAATACTAAAGACAATGAACGTGTTGTGGGCTTTCACGTA
CTGGGTCCAAATGCTGGAGAAGTTACACAAGGCTTTGCAGCTGCGCTCAAATGTGGACTG
ACCAAAAAGCAGCTGGACAGCACAATTGGAATCCACCCTGTCTGTGCAGAGGTATTCACA
ACATTGTCTGTGACCAAGCGCTCTGGGGCAAGCATCCTCCAGGCTGGCTGCTGA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
7589432	Gasdaska PY, Gasdaska JR, Cochran S, Powis G: Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 1995 Oct 2;373(1):5-9.

# Drug_Target_1_HGNC_ID:
HGNC:12437

# Drug_Target_1_HPRD_ID:
03068

# Drug_Target_1_ID:
3610

# Drug_Target_1_Locus:
12q23-q24.1

# Drug_Target_1_Molecular_Weight:
54707

# Drug_Target_1_Name:
Thioredoxin reductase 1, cytoplasmic

# Drug_Target_1_Number_of_Residues:
499

# Drug_Target_1_PDB_ID:
1H6V

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00070	Pyr_redox
PF02852	Pyr_redox_dim
PF07992	Pyr_redox_2

# Drug_Target_1_Protein_Sequence:
>Thioredoxin reductase 1, cytoplasmic precursor
MNGPEDLPKSYDYDLIIIGGGSGGLAAAKEAAQYGKKVMVLDFVTPTPLGTRWGLGGTCV
NVGCIPKKLMHQAALLGQALQDSRNYGWKVEETVKHDWDRMIEAVQNHIGSLNWGYRVAL
REKKVVYENAYGQFIGPHRIKATNNKGKEKIYSAERFLIATGERPRYLGIPGDKEYCISS
DDLFSLPYCPGKTLVVGASYVALECAGFLAGIGLDVTVMVRSILLRGFDQDMANKIGEHM
EEHGIKFIRQFVPIKVEQIEAGTPGRLRVVAQSTNSEEIIEGEYNTVMLAIGRDACTRKI
GLETVGVKINEKTGKIPVTDEEQTNVPYIYAIGDILEDKVELTPVAIQAGRLLAQRLYAG
STVKCDYENVPTTVFTPLEYGACGLSEEKAVEKFGEENIEVYHSYFWPLEWTIPSRDNNK
CYAKIICNTKDNERVVGFHVLGPNAGEVTQGFAAALKCGLTKKQLDSTIGIHPVCAEVFT
TLSVTKRSGASILQAGCCG

# Drug_Target_1_Reaction:
thioredoxin + NADP+ = thioredoxin disulfide + NADPH + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Thioredoxin + NADP(+) = thioredoxin disulfide + NADPH

# Drug_Target_1_SwissProt_ID:
Q16881

# Drug_Target_1_SwissProt_Name:
TRXR1_HUMAN

# Drug_Target_1_Synonyms:
EC 1.8.1.9
TR
TR1
Thioredoxin reductase 1, cytoplasmic precursor

# Drug_Target_1_Theoretical_pI:
6.43

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M64446

# Drug_Target_2_GenBank_ID_Protein:
149631

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
zwf

# Drug_Target_2_Gene_Sequence:
>1461 bp
ATGGTTTCAGAAATCAAGACGTTAGTAACTTTCTTTGGTGGCACTGGTGACTTGGCCAAG
CGTAAGCTTTACCCATCAGTTTTCAATCTTTATAAAAAAGGCTACTTGCAAAAGCATTTT
GCCATTGTTGGAACGGCCCGTCAAGCCCTCAATGATGACGAATTCAAACAATTGGTTCGT
GATTCAATTAAAGATTTCACTGACGATCAAGCACAAGCTGAGGCGTTCATCGAACATTTC
TCATACCGTGCACACGACGTAACAGATGCTGCTTCATACGCTGTTTTAAAAGAGGCGATT
GAAGAAGCTGCCGACAAATTTGATATCGATGGCAACCGCATTTTCTATATGTCAGTTGCG
CCACGTTTCTTTGGTACAATTGCCAAATATCTTAAGTCAGAAGGCCTACTAGCTGACACT
GGTTACAACCGTTTGATGATTGAAAAGCCTTTCGGTACATCATATGACACAGCTGCCGAA
CTCCAAAATGACTTGGAAAACGCATTTGATGATAACCAACTATTCCGTATTGACCACTAC
CTTGGTAAGGAAATGGTTCAAAACATTGCTGCCCTTCGCTTTGGTAACCCAATTTTCGAT
GCTGCTTGGAACAAGGATTACATCAAGAACGTTCAAGTAACATTGTCAGAAGTCTTGGGT
GTCGAAGAACGTGCCGGCTACTATGACACAGCCGGTGCATTGCTTGACATGATTCAAAAC
CACACCATGCAAATTGTTGGTTGGTTAGCCATGGAAAAACCAGAATCATTCACTGACAAA
GACATTCGTGCCGCTAAAAACGCAGCCTTTAATGCTTTGAAGATCTATGATGAAGCAGAA
GTTAACAAATACTTTGTTCGTGCACAATATGGTGCCGGTGATTCAGCTGACTTCAAGCCA
TACCTTGAAGAATTAGACGTACCTGCTGATTCTAAAAACAATACCTTCATCGCCGGCGAA
TTGCAATTTGATTTGCCACGTTGGGAGGGTGTCCCATTCTATGTCCGTTCAGGTAAGCGC
TTAGCTGCTAAACAGACACGGGTTGATATCGTCTTTAAGGCTGGCACGTTTAACTTTGGT
TCAGAACAAGAAGCACAAGAAGCTGTCTTGTCAATTATCATTGATCCAAAGGGTGCTATC
GAATTGAAGTTGAACGCCAAGTCAGTTGAAGATGCTTTCAACACACGTACAATTGACTTA
GGTTGGACTGTATCTGACGAAGATAAGAAGAACACGCCAGAACCATACGAACGTATGATT
CACGACACTATGAATGGTGATGGCTCTAACTTCGCTGACTGGAATGGCGTTTCAATCGCT
TGGAAGTTCGTTGATGCTATTTCAGCCGTTTATACCGCAGATAAAGCACCACTTGAAACT
TACAAGTCGGGCTCAATGGGTCCTGAAGCATCCGATAAATTATTGGCTGCCAATGGTGAT
GCTTGGGTGTTTAAAGGTTAA

# Drug_Target_2_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_2_General_References:
11106478	Cosgrove MS, Gover S, Naylor CE, Vandeputte-Rutten L, Adams MJ, Levy HR: An examination of the role of asp-177 in the His-Asp catalytic dyad of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase: X-ray structure and pH dependence of kinetic parameters of the D177N mutant enzyme. Biochemistry. 2000 Dec 12;39(49):15002-11.
11106479	Vought V, Ciccone T, Davino MH, Fairbairn L, Lin Y, Cosgrove MS, Adams MJ, Levy HR: Delineation of the roles of amino acids involved in the catalytic functions of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase. Biochemistry. 2000 Dec 12;39(49):15012-21.
1304341	Lee WT, Levy HR: Lysine-21 of Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase participates in substrate binding through charge-charge interaction. Protein Sci. 1992 Mar;1(3):329-34.
2071589	Lee WT, Flynn TG, Lyons C, Levy HR: Cloning of the gene and amino acid sequence for glucose 6-phosphate dehydrogenase from Leuconostoc mesenteroides. J Biol Chem. 1991 Jul 15;266(20):13028-34.
3100332	Bhadbhade MM, Adams MJ, Flynn TG, Levy HR: Sequence identity between a lysine-containing peptide from Leuconostoc mesenteroides glucose-6-phosphate dehydrogenase and an active site peptide from human erythrocyte glucose-6-phosphate dehydrogenase. FEBS Lett. 1987 Jan 26;211(2):243-6.
7881907	Rowland P, Basak AK, Gover S, Levy HR, Adams MJ: The three-dimensional structure of glucose 6-phosphate dehydrogenase from Leuconostoc mesenteroides refined at 2.0 A resolution. Structure. 1994 Nov 15;2(11):1073-87.
9485426	Cosgrove MS, Naylor C, Paludan S, Adams MJ, Levy HR: On the mechanism of the reaction catalyzed by glucose 6-phosphate dehydrogenase. Biochemistry. 1998 Mar 3;37(9):2759-67.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2630

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
54441

# Drug_Target_2_Name:
Glucose-6-phosphate 1-dehydrogenase

# Drug_Target_2_Number_of_Residues:
486

# Drug_Target_2_PDB_ID:
1H94

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00479	G6PD_N
PF02781	G6PD_C

# Drug_Target_2_Protein_Sequence:
>Glucose-6-phosphate 1-dehydrogenase
MVSEIKTLVTFFGGTGDLAKRKLYPSVFNLYKKGYLQKHFAIVGTARQALNDDEFKQLVR
DSIKDFTDDQAQAEAFIEHFSYRAHDVTDAASYAVLKEAIEEAADKFDIDGNRIFYMSVA
PRFFGTIAKYLKSEGLLADTGYNRLMIEKPFGTSYDTAAELQNDLENAFDDNQLFRIDHY
LGKEMVQNIAALRFGNPIFDAAWNKDYIKNVQVTLSEVLGVEERAGYYDTAGALLDMIQN
HTMQIVGWLAMEKPESFTDKDIRAAKNAAFNALKIYDEAEVNKYFVRAQYGAGDSADFKP
YLEELDVPADSKNNTFIAGELQFDLPRWEGVPFYVRSGKRLAAKQTRVDIVFKAGTFNFG
SEQEAQEAVLSIIIDPKGAIELKLNAKSVEDAFNTRTIDLGWTVSDEDKKNTPEPYERMI
HDTMNGDGSNFADWNGVSIAWKFVDAISAVYTADKAPLETYKSGSMGPEASDKLLAANGD
AWVFKG

# Drug_Target_2_Reaction:
D-glucose 6-phosphate + NADP+ = D-glucono-1,5-lactone 6-phosphate + NADPH + H+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
D-glucose 6-phosphate + NADP(+) = D-glucono- 1,5-lactone 6-phosphate + NADPH

# Drug_Target_2_SwissProt_ID:
P11411

# Drug_Target_2_SwissProt_Name:
G6PD_LEUME

# Drug_Target_2_Synonyms:
EC 1.1.1.49
G6PD

# Drug_Target_2_Theoretical_pI:
4.57

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L01699

# Drug_Target_3_GenBank_ID_Protein:
13929426

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
PTR1

# Drug_Target_3_Gene_Sequence:
>867 bp
ATGACTGCTCCGACCGTGCCGGTGGCGTTGGTAACAGGCGCCGCGAAGCGTCTTGGCCGC
AGTATCGCTGAGGGACTCCACGCGGAGGGGTACGCTGTCTGCTTGCACTATCATCGCTCT
GCTGCAGAAGCGAACGCACTATCCGCGACGCTCAACGCAAGGCGACCGAACAGCGCCATC
ACGGTGCAGGCGGATCTGAGCAACGTTGCCACAGCCCCGGTCAGCGGCGCTGATGGCTCT
GCACCTGTTACCCTCTTCACGCGCTGTGCTGAGTTGGTGGCTGCGTGCTACACCCACTGG
GGACGCTGCGACGTGCTAGTGAACAACGCCTCTTCTTTCTACCCCACGCCGCTGCTGAGG
AATGACGAGGATGGACACGAGCCCTGTGTCGGAGATAGAGAGGCAATGGAGACGGCCACC
GCTGACCTCTTCGGCTCCAACGCGATAGCGCCCTACTTCTTGATTAAGGCGTTCGCGCAT
CGCTTCGCGGGCACCCCAGCCAAGCATCGCGGCACCAACTACTCCATCATCAACATGGTC
GACGCCATGACGAACCAGCCTCTTCTCGGGTACACCATATATACCATGGCCAAAGGGGCG
TTGGAGGGGCTGACACGGTCTGCCGCGCTGGAGCTTGCGCCGCTGCAGATTCGAGTGAAC
GGCGTTGGTCCGGGTTTGTCGGTGCTCGTCGATGACATGCCCCCTGCTGTGTGGGAGGGC
CACCGCAGCAAGGTGCCTCTGTACCAGCGCGATTCCTCCGCCGCAGAGGTGAGCGACGTT
GTTATCTTTCTGTGCTCCTCCAAGGCCAAGTACATCACCGGCACCTGTGTCAAAGTGGAT
GGTGGCTACAGCCTTACCCGGGCCTGA

# Drug_Target_3_General_Function:
Lipid transport and metabolism

# Drug_Target_3_General_References:
1339441	Callahan HL, Beverley SM: A member of the aldoketo reductase family confers methotrexate resistance in Leishmania. J Biol Chem. 1992 Dec 5;267(34):24165-8.
7972081	Bello AR, Nare B, Freedman D, Hardy L, Beverley SM: PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11442-6.
9153248	Nare B, Hardy LW, Beverley SM: The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. J Biol Chem. 1997 May 23;272(21):13883-91.
9521731	Luba J, Nare B, Liang PH, Anderson KS, Beverley SM, Hardy LW: Leishmania major pteridine reductase 1 belongs to the short chain dehydrogenase family: stereochemical and kinetic evidence. Biochemistry. 1998 Mar 24;37(12):4093-104.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2675

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
30457

# Drug_Target_3_Name:
Pteridine reductase 1

# Drug_Target_3_Number_of_Residues:
288

# Drug_Target_3_PDB_ID:
1E92

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_3_Protein_Sequence:
>Pteridine reductase 1
MTAPTVPVALVTGAAKRLGRSIAEGLHAEGYAVCLHYHRSAAEANALSATLNARRPNSAI
TVQADLSNVATAPVSGADGSAPVTLFTRCAELVAACYTHWGRCDVLVNNASSFYPTPLLR
NDEDGHEPCVGDREAMETATADLFGSNAIAPYFLIKAFAHRFAGTPAKHRGTNYSIINMV
DAMTNQPLLGYTIYTMAKGALEGLTRSAALELAPLQIRVNGVGPGLSVLVDDMPPAVWEG
HRSKVPLYQRDSSAAEVSDVVIFLCSSKAKYITGTCVKVDGGYSLTRA

# Drug_Target_3_Reaction:
5,6,7,8-tetrahydrobiopterin + 2 NADP+ = biopterin + 2 NADPH + 2 H+

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Exhibits a NADPH-dependent biopterin reductase activity. Has good activity with folate and significant activity with dihydrofolate and dihydrobiopterin, but not with quinonoid dihydrobiopterin. Confers resistance to methotrexate (MTX)

# Drug_Target_3_SwissProt_ID:
Q01782

# Drug_Target_3_SwissProt_Name:
PTR1_LEIMA

# Drug_Target_3_Synonyms:
EC 1.5.1.33
H region methotrexate resistance protein

# Drug_Target_3_Theoretical_pI:
7.19

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Periplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M97379

# Drug_Target_4_GenBank_ID_Protein:
155588

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
gfo

# Drug_Target_4_Gene_Sequence:
>1320 bp
ATGACGAACAAAATCTCGTCTTCAGATAATCTTTCCAATGCTGTTTCAGCAACGGATGAC
AACGCTTCCCGTACGCCAAATCTGAACCGTCGCGCTCTCGTTGGTGGTGGTGTTGGACTG
GCCGCACGTGGCGCCTTAGCCAGTGGTCTTCAGGCAGCGACGCTTCCTGCTGGTGCCAGC
CTGGTTCCGACCACGCCTGCAGGTCGCCCGATGCCTTACGCGATCCGCCCGATGCCGGAA
GATCGTCGTTTCGGTTATGCTATCGTCGGTCTGGGTAAATATGCCCTTAACCAGATTTTA
CCGGGTTTTGCCGGATGCCAGCATTCCCGCATGAAGCTTTGGTCAGCGGTAACCGAAAAA
GCTAAAATCGTTGCCGCTGAATATGGCGTCGATCCCCGTAAAATTTATGATTACAGCAAC
TTCGACAAGATCGCTAAAGATCCAAAAATCGACGCTGTTTACATCATTTTGCCAAACTCT
TTGCATGCTGAATTTGCTATCCGTTCTTTCAAAGCCGGCAAGCATGTTATGTGTGAAAAG
CCGATGGCAACCTCTGTTGCTGATTGTCAGCGGATGATCGATGCAGCCAAGGCTGCTAAT
AAAAAGCTGATGATCGGTTACCGTTGCCACTATGATCCAATGAACCGTGCAGCGGTAAAA
TTGATCCGTGAAAACCAGTTGGGTAAACTGGGCATGGTTACCACCGACAACTCAGACGTT
ATGGATCAGAACGACCTGCACAGCAGTGGCGTCTGCGTCGTGAACTCCGGTGGCGGTTCT
TTGATGGATATCGGTATTTATGGCTTGAACGGTACCCGTTACTTGCTGGGTGAAGAACCG
ATCGAAGTCCGTGCTTACACCTACAGCGATCCGAATGATGAACGTTTCGTTGAAGTCGAA
GATCGTATTATTTGGCAGATGCGCTTCAGAAGCGGTGCTCTGTCTCATGGTGCATCTTCT
TATTCGACCACGACGACTTCACGTTTCTCGGTGCAGGGCGACAAAGCTGTTCTGTTGATG
GATCCGGCTACCGGATATTATCAGAATTTGATTTCTGTCCAGACCCCAGGCCATGCTAAC
CAGTCGATGATGCCACAGTTCATCATGCCAGCGAACAACCAGTTCTCTGCACAGTTGGAT
CATCTGGCTGAAGCCGTCATCAATAACAAACCAGTTCGTAGCCCGGGTGAAGAAGGTATG
CAGGATGTGCGCCTGATTCAGGCCATTTATGAAGCAGCTCGTACCGGTCGCGCCGTCAAC
ACGGATTGGGGTTATGTGCGTCAGGTGGTTATTGATTCTGACTTAACCTATTTGGGTTAA

# Drug_Target_4_General_Function:
Involved in oxidoreductase activity

# Drug_Target_4_General_References:
1537789	Kanagasundaram V, Scopes RK: Cloning, sequence analysis, and expression of the structural gene encoding glucose-fructose oxidoreductase from Zymomonas mobilis. J Bacteriol. 1992 Mar;174(5):1439-47.
8472911	Loos H, Sahm H, Sprenger GA: Glucose-fructose oxidoreductase, a periplasmic enzyme of Zymomonas mobilis, is active in its precursor form. FEMS Microbiol Lett. 1993 Mar 1;107(2-3):293-8.
8994968	Kingston RL, Scopes RK, Baker EN: The structure of glucose-fructose oxidoreductase from Zymomonas mobilis: an osmoprotective periplasmic enzyme containing non-dissociable NADP. Structure. 1996 Dec 15;4(12):1413-28.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2826

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
47190

# Drug_Target_4_Name:
Glucose--fructose oxidoreductase

# Drug_Target_4_Number_of_Residues:
433

# Drug_Target_4_PDB_ID:
1H6A

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01408	GFO_IDH_MocA
PF02894	GFO_IDH_MocA_C

# Drug_Target_4_Protein_Sequence:
>Glucose--fructose oxidoreductase precursor
MTNKISSSDNLSNAVSATDDNASRTPNLTRRALVGGGVGLAAAGALASGLQAATLPAGAS
QVPTTPAGRPMPYAIRPMPEDRRFGYAIVGLGKYALNQILPGFAGCQHSRIEALVSGNAE
KAKIVAAEYGVDPRKIYDYSNFDKIAKDPKIDAVYIILPNSLHAEFAIRAFKAGKHVMCE
KPMATSVADCQRMIDAAKAANKKLMIGYRCHYDPMNRAAVKLIRENQLGKLGMVTTDNSD
VMDQNDPAQQWRLRRELAGGGSLMDIGIYGLNGTRYLLGEEPIEVRAYTYSDPNDERFVE
VEDRIIWQMRFRSGALSHGASSYSTTTTSRFSVQGDKAVLLMDPATGYYQNLISVQTPGH
ANQSMMPQFIMPANNQFSAQLDHLAEAVINNKPVRSPGEEGMQDVRLIQAIYEAARTGRP
VNTDWGYVRQGGY

# Drug_Target_4_Reaction:
D-glucose + D-fructose = D-gluconolactone + D-glucitol

# Drug_Target_4_Signals:
1-52

# Drug_Target_4_Specific_Function:
D-glucose + D-fructose = D-gluconolactone + D- glucitol

# Drug_Target_4_SwissProt_ID:
Q07982

# Drug_Target_4_SwissProt_Name:
GFO_ZYMMO

# Drug_Target_4_Synonyms:
EC 1.1.99.28
GFOR
Glucose--fructose oxidoreductase precursor

# Drug_Target_4_Theoretical_pI:
8.73

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
DPYD

# Drug_Target_5_GenBank_ID_Gene:
U09178

# Drug_Target_5_GenBank_ID_Protein:
558305

# Drug_Target_5_GeneCard_ID:
DPYD

# Drug_Target_5_Gene_Name:
DPYD

# Drug_Target_5_Gene_Sequence:
>3078 bp
ATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATCGAGAGTATCCTGGCTTTAAATCCT
CGAACACAAACTCATGCAACTCTGTGTTCCACTTCGGCCAAGAAATTAGACAAGAAACAT
TGGAAAAGAAATCCTGATAAGAACTGCTTTAATTGTGAGAAGCTGGAGAATAATTTTGAT
GACATCAAGCACACGACTCTTGGTGAGCGAGGAGCTCTCCGAGAAGCAATGAGATGCCTG
AAATGTGCAGATGCCCCGTGTCAGAAGAGCTGTCCAACTAATCTTGATATTAAATCATTC
ATCACAAGTATTGCAAACAAGAACTATTATGGAGCTGCTAAGATGATATTTTCTGACAAC
CCACTTGGTCTGACTTGTGGAATGGTATGTCCAACCTCTGATCTATGTGTAGGTGGATGC
AATTTATATGCCACTGAAGAGGGACCCATTAATATTGGTGGATTGCAGCAATTTGCTACT
GAGGTATTCAAAGCAATGAGTATCCCACAGATCAGAAATCCTTCGCTGCCTCCCCCAGAA
AAAATGTCTGAAGCCTATTCTGCAAAGATTGCTCTTTTTGGTGCTGGGCCTGCAAGTATA
AGTTGTGCTTCCTTTTTGGCTCGATTGGGGTACTCTGACATCACTATATTTGAAAAACAA
GAATATGTTGGTGGTTTAAGTACTTCTGAAATTCCTCAGTTCCGGCTGCCGTATGATGTA
GTGAATTTTGAGATTGAGCTAATGAAGGACCTTGGTGTAAAGATAATTTGCGGTAAAAGC
CTTTCAGTGAATGAAATGACTCTTAGCACTTTGAAAGAAAAAGGCTACAAAGCTGCTTTC
ATTGGAATAGGTTTGCCAGAACCCAATAAAGATGCCATCTTCCAAGGCCTGACGCAGGAC
CAGGGGTTTTATACATCCAAAGACTTTTTGCCACTTGTAGCCAAAGGCAGTAAAGCAGGA
ATGTGCGCCTGTCACTCTCCATTGCCATCGATACGGGGAGTCGTGATTGTACTTGGAGCT
GGAGACACTGCCTTCGACTGTGCAACATCTGCTCTACGTTGTGGAGCTCGCCGAGTGTTC
ATCGTCTTCAGAAAAGGCTTTGTTAATATAAGAGCTGTCCCTGAGGAGATGGAGCTTGCT
AAGGAAGAAAAGTGTGAATTTCTGCCATTCCTGTCCCCACGGAAGGTTATAGTAAAAGGT
GGGAGAATTGTTGCTATGCAGTTTGTTCGGACAGAGCAAGATGAAACTGGAAAATGGAAT
GAAGATGAAGATCAGATGGTCCATCTGAAAGCCGATGTGGTCATCAGTGCCTTTGGTTCA
GTTCTGAGTGATCCTAAAGTAAAAGAAGCCTTGAGCCCTATAAAATTTAACAGATGGGGT
CTCCCAGAAGTAGATCCAGAAACTATGCAAACTAGTGAAGCATGGGTATTTGCAGGTGGT
GATGTCGTTGGTTTGGCTAACACTACAGTGGAATCGGTGAATGATGGAAAGCAAGCTTCT
TGGTACATTCACAAATACGTACAGTCACAATATGGAGCTTCCGTTTCTGCCAAGCCTGAA
CTACCCCTCTTTTACACTCCTATTGATCTGGTGGACATTAGTGTAGAAATGGCCGGATTG
AAGTTTATAAATCCTTTTGGTCTTGCTAGCGCAACTCCAGCCACCAGCACATCAATGATT
CGAAGAGCTTTTGAAGCTGGATGGGGTTTTGCCCTCACCAAAACTTTCTCTCTTGATAAG
GACATTGTGACAAATGTTTCCCCCAGAATCATCCGGGGAACCACCTCTGGCCCCATGTAT
GGCCCTGGACAAAGCTCCTTTCTGAATATTGAGCTCATCAGTGAGAAAACGGCTGCATAT
TGGTGTCAAAGTGTCACTGAACTAAAGGCTGACTTCCCAGACAACATTGTGATTGCTAGC
ATTATGTGCAGTTACAATAAAAATGACTGGACGGAACTTGCCAAGAAGTCTGAGGATTCT
GGAGCAGATGCCCTGGAGTTAAATTTATCATGTCCACATGGCATGGGAGAAAGAGGAATG
GGCCTGGCCTGTGGGCAGGATCCAGAGCTGGTGCGGAACATCTGCCGCTGGGTTAGGCAA
GCTGTTCAGATTCCTTTTTTTGCCAAGCTGACCCCAAATGTCACTGATATTGTGAGCATC
GCAAGAGCTGCAAAGGAAGGTGGTGCCAATGGCGTTACAGCCACCAACACTGTCTCAGGT
CTGATGGGATTAAAATCTGATGGCACACCTTGGCCAGCAGTGGGGATTGCAAAGCGAACT
ACATATGGAGGAGTGTCTGGGACAGCAATCAGACCTATTGCTTTGAGAGCTGTGACCTCC
ATTGCTCGTGCTCTGCCTGGATTTCCCATTTTGGCTACTGGTGGAATTGACTCTGCTGAA
AGTGGTCTTCAGTTTCTCCATAGTGGTGCTTCCGTCCTCCAGGTATGCAGTGCCATTCAG
AATCAGGATTTCACTGTGATCGAAGACTACTGCACTGGCCTCAAAGCCCTGCTTTATCTG
AAAAGCATTGAAGAACTACAAGACTGGGATGGACAGAGTCCAGCTACTGTGAGTCACCAG
AAAGGGAAACCAGTTCCACGTATAGCTGAACTCATGGACAAGAAACTGCCAAGTTTTGGA
CCTTATCTGGAACAGCGCAAGAAAATCATAGCAGAAAACAAGATTAGACTGAAAGAACAA
AATGTAGCTTTTTCACCACTTAAGAGAAGCTGTTTTATCCCCAAAAGGCCTATTCCTACC
ATCAAGGATGTAATAGGAAAAGCACTGCAGTACCTTGGAACATTTGGTGAATTGAGCAAC
GTAGAGCAAGTTGTGGCTATGATTGATGAAGAAATGTGTATCAACTGTGGTAAATGCTAC
ATGACCTGTAATGATTCTGGCTACCAGGCTATACAGTTTGATCCAGAAACCCACCTGCCC
ACCATAACCGACACTTGTACAGGCTGTACTCTGTGTCTCAGTGTTTGCCCTATTGTCGAC
TGCATCAAAATGGTTTCCAGGACAACACCTTATGAACCAAAGAGAGGCGTACCCTTATCT
GTGAATCCGGTGTGTTAA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
1512248	Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem. 1992 Aug 25;267(24):17102-9.
8083224	Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994 Sep 16;269(37):23192-6.
8892022	Vreken P, Van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, van Gennip AH: A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19(5):645-54.
9135003	Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 1997 May 1;57(9):1660-3.
9170156	Fernandez-Salguero PM, Sapone A, Wei X, Holt JR, Jones S, Idle JR, Gonzalez FJ: Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics. 1997 Apr;7(2):161-3.
9266349	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherit Metab Dis. 1997 Jul;20(3):335-8.
9439663	Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH: Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet. 1997 Dec;101(3):333-8.
9464498	Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y, Watabe T: Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett. 1998 Jan 9;122(1-2):107-13.

# Drug_Target_5_HGNC_ID:
HGNC:3012

# Drug_Target_5_HPRD_ID:
02036

# Drug_Target_5_ID:
1302

# Drug_Target_5_Locus:
1p22

# Drug_Target_5_Molecular_Weight:
111375

# Drug_Target_5_Name:
Dihydropyrimidine dehydrogenase [NADP+]

# Drug_Target_5_Number_of_Residues:
1025

# Drug_Target_5_PDB_ID:
1GTE

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00037	Fer4
PF01180	DHO_dh
PF07992	Pyr_redox_2

# Drug_Target_5_Protein_Sequence:
>Dihydropyrimidine dehydrogenase [NADP+] precursor
MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFD
DIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDN
PLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPE
KMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDV
VNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQD
QGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVF
IVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWN
EDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGG
DVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGL
KFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMY
GPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDS
GADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSI
ARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTS
IARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYL
KSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQ
NVAFSPLKRSCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCY
MTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLS
VNPVC

# Drug_Target_5_Reaction:
5,6-dihydrouracil + NADP+ = uracil + NADPH + H+

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil

# Drug_Target_5_SwissProt_ID:
Q12882

# Drug_Target_5_SwissProt_Name:
DPYD_HUMAN

# Drug_Target_5_Synonyms:
DHPDHase
DPD
Dihydropyrimidine dehydrogenase precursor
Dihydrothymine dehydrogenase
Dihydrouracil dehydrogenase
EC 1.3.1.2

# Drug_Target_5_Theoretical_pI:
7.05

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Mitochondrion

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
AASS

# Drug_Target_6_GenBank_ID_Gene:
AF229180

# Drug_Target_6_GenBank_ID_Protein:
7264724

# Drug_Target_6_GeneCard_ID:
AASS

# Drug_Target_6_Gene_Name:
AASS

# Drug_Target_6_Gene_Sequence:
>2781 bp
ATGCTGCAAGTACATAGGACTGGACTGGGCAGGCTGGGGGTCAGCCTCTCCAAGGGTCTT
CACCACAAAGCTGTGTTGGCCGTCCGGAGGGAGGATGTGAACGCCTGGGAGAGAAGGGCC
CCGCTAGCTCCCAAGCACATCAAAGGCATCACCAATCTGGGATACAAGGTCTTGATACAG
CCTTCGAATCGGCGGGCCATTCATGATAAGGACTATGTCAAAGCTGGTGGCATTCTTCAG
GAGGATATTTCTGAAGCTTGTCTAATTTTAGGAGTTAAAAGACCTCCAGAGGAAAAATTA
ATGTCCAGGAAGACTTATGCATTTTTCTCCCACACAATAAAAGCTCAGGAGGCCAATATG
GGCTTGTTGGATGAGATTCTAAAACAGGAAATTCGCCTTATTGATTATGAGAAAATGGTG
GATCATAGAGGAGTACGGGTAGTGGCATTTGGACAGTGGGCTGGTGTGGCAGGAATGATC
AACATTTTACATGGAATGGGTTTAAGGCTCCTTGCTTTGGGACATCACACACCTTTTATG
CACATTGGCATGGCTCATAACTACAGGAATAGCAGTCAGGCTGTGCAAGCTGTCCGTGAT
GCTGGCTATGAAATATCTTTGGGTTTGATGCCTAAGTCAATAGGACCCTTAACATTTGTG
TTCACAGGAACTGGTAATGTTTCTAAGGGAGCCCAAGCAATCTTTAATGAGCTACCTTGT
GAATATGTGGAGCCCCATGAATTAAAAGAAGTTTCCCAAACTGGAGACCTCAGAAAAGTG
TATGGGACGGTGTTAAGTCGTCATCATCATCTTGTCAGGAAAACAGATGCTGTGTATGAT
CCTGCAGAGTATGACAAACATCCGGAGCGCTACATAAGTCGTTTTAATACTGATATTGCA
CCCTATACAACTTGCTTAATTAATGGAATCTACTGGGAACAAAACACTCCTCGCCTCCTA
ACCCGCCAAGATGCTCAGAGTCTCCTGGCTCCGGGCAAGTTCTCACCTGCTGGTGTGGAA
GGCTGCCCTGCATTACCACACAAACTCGTGGCAATATGTGACATTTCAGCTGACACAGGA
GGGTCTATAGAGTTTATGACTGAGTGTACAACAATAGAGCATCCCTTTTGCATGTATGAT
GCAGACCAGCATATTATTCATGACAGTGTTGAAGGCTCGGGGATCCTGATGTGTTCCATT
GACAATTTGCCGGCACAGCTCCCAATTGAAGCTACAGAATGCTTTGGAGACATGCTTTAC
CCTTATGTTGAAGAAATGATATTATCAGACGCGACACAGCCTCTTGAAAGTCAGAATTTT
TCTCCTGTGGTGAGAGATGCAGTGATTACATCCAACGGTACATTACCTGATAAATATAAA
TATATCCAGACACTCCGGGAGAGCAGGGAACGTGCTCAGTCACTTTCAATGGGCACCAGG
AGAAAGGTTTTGGTTCTTGGATCTGGCTACATATCTGAGCCTGTATTAGAATATTTATCA
AGAGATGGCAATATAGAAATAACAGTAGGATCTGACATGAAGAATCAAATTGAACAGTTA
GGCAAGAAATATAATATTAATCCTGTTAGCATGGACATTTGTAAACAAGAAGAGAAGCTG
GGCTTCTTGGTGGCAAAACAGGATCTTGTCATCAGCTTGTTGCCTTATGTATTGCACCCT
CTTGTGGCCAAGGCCTGCATCACAAACAAAGTTAACATGGTCACTGCAAGCTACATCACA
CCAGCACTAAAAGAATTGGAAAAGAGTGTGGAAGATGCTGGCATCACAATCATTGGTGAA
TTGGGATTGGACCCTGGTCTGGATCACATGTTAGCAATGGAAACAATAGATAAAGCCAAG
GAAGTGGGAGCCACGATTGAATCATATATTTCCTACTGTGGTGGGCTTCCAGCCCCTGAA
CATTCAAACAATCCATTGAGATATAAATTTAGCTGGAGTCCAGTGGGAGTTTTGATGAAT
GTAATGCAGTCTGCCACCTATCTGCTCGATGGAAAGGTTGTGAATGTTGCAGGAGGCATC
TCCTTTCTTGATGCCGTTACGTCCATGGATTTTTTTCCAGGATTAAATTTGGAAGGCTAT
CCTAACAGAGACAGTACGAAATATGCTGAGATTTATGGCATTTCTTCTGCTCACACTTTG
TTGCGGGGGACACTGAGATATAAGGGATATATGAAAGCTTTGAATGGATTTGTAAAATTA
GGTCTTATAAACAGAGAAGCGCTTCCTGCCTTTAGACCTGAGGCCAACCCTCTCACCTGG
AAACAACTCCTCTGTGACCTAGTTGGGATTTCACCCTCCTCTGAGCATGATGTGTTGAAG
GAAGCTGTTCTTAAGAAACTAGGAGGAGACAATACCCAGTTGGAGGCTGCTGAATGGTTG
GGCTTACTTGGGGATGAACAAGTTCCTCAGGCAGAGTCCATTCTGGATGCCCTCTCCAAG
CATTTGGTCATGAAGCTTTCCTATGGTCCTGAAGAAAAAGATATGATTGTGATGAGAGAC
AGCTTTGGAATCAGACATCCTTCTGGACATTTAGAACATAAAACGATTGATCTTGTGGCT
TATGGGGACATCAATGGCTTTTCAGCCATGGCTAAAACCGTGGGGTTACCCACCGCCATG
GCAGCCAAAATGTTGCTTGATGGTGAAATTGGAGCCAAAGGCCTAATGGGGCCCTTTTCA
AAGGAGATCTATGGACCAATATTGGAGCGAATTAAAGCAGAAGGCATTATATATACTACA
CAGAGTACAATTAAACCATAA

# Drug_Target_6_General_Function:
Amino acid transport and metabolism

# Drug_Target_6_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.

# Drug_Target_6_HGNC_ID:
HGNC:17366

# Drug_Target_6_HPRD_ID:
05489

# Drug_Target_6_ID:
83

# Drug_Target_6_Locus:
7q31.3

# Drug_Target_6_Molecular_Weight:
102133

# Drug_Target_6_Name:
Alpha-aminoadipic semialdehyde synthase, mitochondrial

# Drug_Target_6_Number_of_Residues:
926

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF01262	AlaDh_PNT_C
PF03435	Saccharop_dh
PF05222	AlaDh_PNT_N

# Drug_Target_6_Protein_Sequence:
>Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
MLQVHRTGLGRLGVSLSKGLHHKAVLAVRREDVNAWERRAPLAPKHIKGITNLGYKVLIQ
PSNRRAIHDKDYVKAGGILQEDISEACLILGVKRPPEEKLMSRKTYAFFSHTIKAQEANM
GLLDEILKQEIRLIDYEKMVDHRGVRVVAFGQWAGVAGMINILHGMGLRLLALGHHTPFM
HIGMAHNYRNSSQAVQAVRDAGYEISLGLMPKSIGPLTFVFTGTGNVSKGAQAIFNELPC
EYVEPHELKEVSQTGDLRKVYGTVLSRHHHLVRKTDAVYDPAEYDKHPERYISRFNTDIA
PYTTCLINGIYWEQNTPRLLTRQDAQSLLAPGKFSPAGVEGCPALPHKLVAICDISADTG
GSIEFMTECTTIEHPFCMYDADQHIIHDSVEGSGILMCSIDNLPAQLPIEATECFGDMLY
PYVEEMILSDATQPLESQNFSPVVRDAVITSNGTLPDKYKYIQTLRESRERAQSLSMGTR
RKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKL
GFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGE
LGLDPGLDHMLAMETIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMN
VMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTL
LRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLK
EAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRD
SFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFS
KEIYGPILERIKAEGIIYTTQSTIKP

# Drug_Target_6_Reaction:
N6-(L-1,3-dicarboxypropyl)-L-lysine + NADP+ + H2O = L-lysine + 2-oxoglutarate + NADPH + H+

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively

# Drug_Target_6_SwissProt_ID:
Q9UDR5

# Drug_Target_6_SwissProt_Name:
AASS_HUMAN

# Drug_Target_6_Synonyms:
Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
EC 1.5.1.8
EC 1.5.1.9
LKR
LKR/SDH
LOR
Saccharopine dehydrogenase

# Drug_Target_6_Theoretical_pI:
6.62

# Drug_Target_6_Transmembrane_Regions:
None

#END_DRUGCARD DB02338
